The planned acquisition will expand Biogen’s presence in immunology and rare diseases with Apellis’ C3 complement therapies, Syfovre® and Empaveli®, which are based on technology developed by John Lambris, PhD, the Dr. Ralph and Sallie Weaver Professor of Research Medicine at Penn Medicine. Read more here.